

# Manufacturing of Homogeneous T Cells using Synthetic Exon/Expression Disruptors (SEEDs)

Tech ID: 33616 / UC Case 2022-093-0

## TECHNOLOGY DESCRIPTION

Current methods of manufacturing T cells produce heterogeneous mixtures of partially engineered T cells. Our scientists have developed a one-step process to immunomagnetically deplete non-modified and partially edited T cells, while also reprogramming three critical loci encoding T cell specificity, co-receptor expression and MHC expression. This strategy produces 98% purity after selection for individual modifications and up to 90% purity for 6 simultaneous edits (3 knock-ins and 3 knockouts). The method is simple, compatible with existing clinical manufacturing workflows and can be readily adapted to other loci to facilitate production of complex gene-edited cell therapies.

## STAGE OF DEVELOPMENT

Characterized editing outcomes and transgene function in cells edited with a single or multiple SEEDs and the ability of SEED-selection to enrich for cells with biallelic integrations in a single step. Demonstrate antibody epitope editing enables enrichment of transgenes and facilitates removal of T cells with mispaired TCRs.

## RELATED MATERIALS

- ▶ [Ultra-high efficiency T cell reprogramming at multiple loci with SEED-Selection](#)

## PATENT STATUS

Country	Type	Number	Dated	Case
Japan	Issued Patent	7834651	03/13/2026	2020-206
Australia	Published Application	WO 2021/183884	09/16/2021	2020-206

## CONTACT

Gemma E. Rooney  
[Gemma.Rooney@ucsf.edu](mailto:Gemma.Rooney@ucsf.edu)  
 tel: 415-625-9093.



## OTHER INFORMATION

### KEYWORDS

Homogeneous T cells,  
 Manufacturing T cells, Edited  
 T cells

### CATEGORIZED AS

- ▶ **Medical**
  - ▶ Disease:
    - Autoimmune and Inflammation
    - Disease: Cancer
  - ▶ Therapeutics

### RELATED CASES

2022-093-0, 2020-206-0

Canada	Published Application	WO 2021/183884	09/16/2021	2020-206
China	Published Application	WO 2021/183884	09/16/2021	2020-206
Israel	Published Application	WO 2021/183884	09/16/2021	2020-206
Mexico	Published Application	WO 2021/183884	09/16/2021	2020-206
Brazil	Published Application			2020-206
European Patent Office	Published Application			2020-206

Additional Patents Pending

ADDRESS

**UCSF**

**Innovation Ventures**

600 16th St, Genentech Hall, S-272,

San Francisco, CA 94158

CONTACT

Tel:

[innovation@ucsf.edu](mailto:innovation@ucsf.edu)

<https://innovation.ucsf.edu>

Fax:

CONNECT

 Follow  Connect

© 2024 - 2026, The Regents of the University of California

[Terms of use](#) [Privacy Notice](#)